WallStSmart
FBLG

FibroBiologics, Inc. Common Stock

NASDAQ: FBLG · HEALTHCARE · BIOTECHNOLOGY

$1.13
-6.25% today

Updated 2026-06-02

Market cap
$4.01M
P/E ratio
P/S ratio
EPS (TTM)
$-7.02
Dividend yield
52W range
$1 – $15
Volume
0.6M

FibroBiologics, Inc. Common Stock (FBLG) Financial statements

SEC filings — annual and quarterly data.

Income statement — annual

Item20212022202320242025
Revenue$0.00$0.00$0.00$0.00
Revenue growth (YoY)
Cost of revenue$94000.00$437000.00$573000.00
Gross profit$-94000.00$-437000.00$-573000.00
Gross margin
R&D$669000.00$521000.00$1.15M$2.37M$4.50M
SG&A$500000.00$1.06M$3.32M$6.52M$9.23M
Operating income$-1.17M$-1.58M$-4.47M$-8.89M$-13.74M
Operating margin
EBITDA$-1.58M$-4.37M$-15.90M$-10.57M
EBITDA margin
EBIT$-4.47M$-16.34M$-11.14M
Interest expense$4000.00$654000.00$147000.00$20000.00
Income tax
Effective tax rate0.0%0.0%0.0%0.0%0.0%
Net income$-1.17M$-1.58M$-5.12M$-16.48M$-11.16M
Net income growth (YoY)-35.3%-223.7%-221.9%+32.3%
Profit margin

Frequently asked questions

How much free cash flow does FBLG generate?

FBLG produced $-12.09M in free cash flow in its most recent fiscal year. Free cash flow is what is left after running and reinvesting in the business, and it is the cash that actually funds buybacks, dividends, and a stronger balance sheet.

Is FBLG's balance sheet healthy?

FBLG holds $13.98M in cash and equivalents against — in long-term debt, on $2.73M of shareholder equity. That debt is best read against the cash flow the business throws off each year.